It’s been quite a year for Akcea Therapeutics (AKCA). After going public in July 2017, the Cambridge, Mass., company almost immediately filed for FDA approval on two drugs for rare diseases.
Volanesorsen, also known as Waylivra, is intended to treat familial chylomicronemia syndrome (FCS), a condition that leads to a buildup of fat in organs. Inotersen, which has the brand name Tegsedi, treats hereditary transthyretin amyloidosis, known as hATTR for short. The condition leads to a buildup of proteins that can cause issues in the nerves and heart. European authorities have already approved inotersen, and the FDA is set to decide on both those drugs before the end of the year.
The anticipated approvals have sparked a growth spurt, Akcea CEO Paula Soteropoulos told STAT in the firm’s offices. The company has doubled its workforce and established teams in nine countries, and its headquarters will be moving from its current space by the river in Cambridge to a larger space in Boston’s Seaport in September.
About the Author Reprints
Excellent commentary.
Hope that both innovative products succeed by
having a fairly even physician/ patient preference,
if they can’t be differentiated in any other way.
CEO should ideally always be diversity neutral;
just need the best person available to do a job well.
Diversities naturally 8 which politician want to lose himself also don’t want to get down money rates if they don’t continue so soon lose all because if somebody take Africa market so and mark its all money come back and that countries so that time is very horrible I think so